AGP Executive Report
Last update: 2 hours agoStroke Prevention: FDA approved asundexian, the first factor XIa inhibitor, to reduce repeat-stroke risk after certain ischemic strokes or high-risk TIAs; it cut ischemic stroke risk by 26% in a trial when added to antiplatelet therapy. Cell and Gene Therapies: New FDA guidance calls for manufacturers to manage potency across a therapy’s lifecycle, from raw materials and production to testing and post-approval monitoring. Rural Access: Missouri secured $218 million in its second year of federal rural-health funding, following a first-year award that supported care hubs across 104 rural counties. Maternal and Newborn Care: Lagos is developing an emergency-care framework to strengthen staff skills, clinical coordination and facilities and reduce preventable deaths. Workplace Health: The American Medical Association backed a near-total U.S. ban on high-silica engineered stone, linked to incurable, sometimes fatal silicosis among workers. Regulatory Burden: CMS proposed changes it says could save $320 million and cut more than 3.26 million hours of administrative work for healthcare providers.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
